Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Galectin Therapeutics ( (GALT) ) has shared an update.
On January 10, 2026, Galectin Therapeutics, Inc. announced that Marc Rubin resigned from its Board of Directors. The company specified that Rubin’s departure did not stem from any disagreement regarding its operations, policies or practices, suggesting no immediate disruption to governance or strategic direction for stakeholders.
The most recent analyst rating on (GALT) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Galectin Therapeutics stock, see the GALT Stock Forecast page.
Spark’s Take on GALT Stock
According to Spark, TipRanks’ AI Analyst, GALT is a Neutral.
The score is held down primarily by very weak financial performance (no meaningful revenue, heavy losses, negative equity, and continued cash burn with rising debt). Technicals also reflect a soft trend with negative momentum signals. Offsetting these, recent clinical/regulatory progress and insider financing support are positives but not enough to overcome the current financial risk profile.
To see Spark’s full report on GALT stock, click here.
More about Galectin Therapeutics
Average Trading Volume: 530,512
Technical Sentiment Signal: Buy
Current Market Cap: $206.3M
For an in-depth examination of GALT stock, go to TipRanks’ Overview page.